Blood Pressure Drug Boosts Cancer Medication Levels in Rat Study, Raising Interaction Concerns

A cancer drug and a common blood pressure medication, when taken together, appear to dramatically change how the body handles one of them, according to a new pharmacokinetic study in rats. Researchers at Liuzhou People’s Hospital in Guangxi, China, found that co-administering anlotinib, an oral anticancer agent, with amlodipine besylate, one of the most widely prescribed antihypertensive drugs in the world, roughly doubled the concentration of amlodipine in the animals’ blood after a single dose and nearly tripled its total exposure after repeated dosing. Anlotinib, by contrast, was left essentially untouched. The findings, published as an open access research article in BMC Pharmacology and Toxicology, add a clinically important cautionary note for cancer patients who also take medication for hypertension.

The study was designed to answer a deceptively simple question: what happens to the levels of two drugs in the body when they are given at the same time? Both anlotinib and amlodipine are taken orally, both circulate widely in the bloodstream, and both are processed by the same cellular machinery in the liver and intestine. That overlap creates the potential for what pharmacologists call a drug-drug interaction, in which one compound slows, accelerates, or otherwise alters the absorption, distribution, metabolism, or elimination of another. When that happens, a drug that is normally safe at its prescribed dose can accumulate to dangerous levels, or conversely fall below the threshold needed to work.

To investigate, the team used Sprague-Dawley rats, a standard laboratory strain weighing between 180 and 220 grams, obtained from Hunan SJA Laboratory Animal Co., Ltd. All protocols were approved by the Ethics Committee of Liuzhou People’s Hospital under approval number LRYIACUC2024008. The animals were randomly divided into three groups. The first received anlotinib alone at a dose of 6 milligrams per kilogram of body weight, delivered by oral gavage, a technique in which liquid medication is placed directly into the stomach. The second received amlodipine besylate alone at 4 milligrams per kilogram, also by gavage. The third group received both drugs simultaneously at the same doses. The researchers then drew blood samples over time and measured the concentration of each drug in plasma using a validated liquid chromatography-tandem mass spectrometry method, commonly abbreviated LC-MS/MS.

LC-MS/MS is the gold standard for this kind of work. Liquid chromatography first separates the complex mixture of molecules in a plasma sample, and tandem mass spectrometry then identifies and quantifies the target compounds with extraordinary sensitivity, detecting them at concentrations far below what older techniques could manage. From the resulting concentration-time data, the team plotted mean plasma curves and calculated pharmacokinetic parameters using non-compartmental modeling, a widely used mathematical approach that does not assume any particular structure for how the drug moves through the body. The key parameters include Cmax, the peak concentration reached in the blood; AUC, the area under the concentration-time curve, which represents total drug exposure over time; clearance, the rate at which the body removes the drug; and half-life, the time it takes for the drug concentration to fall by half.

The results were strikingly one-sided. After a single dose, rats given both drugs showed a peak amlodipine concentration 2.34 times higher than rats given amlodipine alone, and total amlodipine exposure over the observation period, measured as AUC from time zero to the last measurable time point, rose to 2.01 times the control value. Clearance, meanwhile, dropped by 64.4 percent, meaning the animals were removing amlodipine from their circulation at less than half the normal rate. All of these differences were statistically significant at the conventional threshold of P less than 0.05.

Repeated dosing told an even more dramatic story. When the drugs were given multiple times, the total amlodipine exposure extrapolated to infinity, AUC from zero to infinity, climbed to 3.30 times the value seen with amlodipine alone. The drug’s half-life stretched to 2.73 times its usual length, and clearance fell by 64.9 percent, essentially matching the single-dose reduction. In practical terms, the combination turned amlodipine from a drug the body clears steadily into one that lingers and accumulates, with each successive dose building on the residue of the last. For a medication whose therapeutic and adverse effects are directly tied to blood concentration, that kind of accumulation matters.

Anlotinib, however, marched to its own drummer. Across both the single-dose and multiple-dose experiments, none of its pharmacokinetic parameters changed significantly when amlodipine was on board, with all comparisons showing P greater than 0.05. The interaction, in other words, flows in one direction only: anlotinib profoundly reshapes amlodipine’s journey through the body, while amlodipine leaves anlotinib alone. This asymmetry is itself informative, because it suggests a specific mechanism rather than a general perturbation of the animals’ physiology.

Although the study did not directly identify the molecular culprit, the pattern is consistent with what is known about how these drugs are metabolized. Both anlotinib and amlodipine are substrates of the cytochrome P450 enzyme family, the liver’s principal drug-processing assembly line, and amlodipine in particular depends heavily on the CYP3A4 enzyme for its breakdown. Anlotinib has been reported in the literature to interact with cytochrome P450 pathways, and the authors’ finding that amlodipine clearance falls sharply while its absorption-related parameters rise points toward inhibition of amlodipine’s metabolic clearance as the most likely explanation. When CYP3A4 activity is suppressed, amlodipine lingers in the intestine and liver longer, more of it enters the bloodstream, and less of it is cleared per unit time, exactly the signature the rat data display. The authors note that the precise mechanistic confirmation would require further work, and the study was designed to characterize the interaction rather than to pin down its enzymatic basis.

Why does this matter beyond the laboratory? Anlotinib is an oral multi-target tyrosine kinase inhibitor approved in China for the treatment of several advanced cancers, including non-small cell lung cancer, small cell lung cancer, soft tissue sarcoma, and ovarian cancer, and it is increasingly used in combination regimens. Cancer patients are frequently older and carry cardiovascular comorbidities, and hypertension is among the most common. Amlodipine is a first-line antihypertensive, a dihydropyridine calcium channel blocker that relaxes blood vessels and is taken daily by tens of millions of people worldwide. The overlap between the population taking anlotinib and the population taking amlodipine is therefore substantial, and until now, the pharmacokinetic consequences of combining them had not been formally characterized in a controlled animal study.

Elevated amlodipine exposure is not a trivial side effect. Excessive amlodipine levels can cause profound hypotension, dizziness, peripheral edema, reflex tachycardia, and in severe cases cardiovascular instability, complications that are particularly dangerous for patients already weakened by cancer and its treatment. The rat findings, showing exposure increases of two- to three-fold, fall squarely in the range that clinicians would consider clinically significant. The study’s conclusion is direct: potential drug-drug interactions should be considered when anlotinib and amlodipine are co-administered in clinical practice to ensure safe and rational medication use. In a hospital setting, that could translate into closer blood pressure monitoring, dose adjustment of amlodipine, or selection of an alternative antihypertensive that does not share the same metabolic pathway.

The authors, Ruijie Xie and Yueling Huang, who share first authorship, along with Zhiling Liu, Tingyan Wei, and corresponding author Chengyu Liu, emphasize that their work was conducted in rats, and rodent pharmacokinetics do not always translate directly to humans. Doses were also chosen to characterize the interaction clearly rather than to mirror exact clinical dosing. Nevertheless, animal interaction studies of this kind are a standard and necessary early step in identifying combinations that warrant clinical vigilance, and the magnitude of the effect observed here is large enough that it would be imprudent to ignore. The study received no external funding, and the authors declare no competing interests. As anlotinib’s clinical footprint expands and as more cancer patients live long enough to require chronic cardiovascular medication, studies like this one serve as a reminder that the drugs we combine are never truly independent actors. Each prescription is a chemistry experiment conducted inside the patient, and the task of modern pharmacology is to predict the outcome before the experiment begins.

Subject of Research: Pharmacokinetic drug-drug interaction between anlotinib and amlodipine besylate in rats

Article Title: Pharmacokinetic interaction between anlotinib and amlodipine besylate in rats

Article References: Xie, R., Huang, Y., Liu, Z., Wei, T., & Liu, C. (2026). Pharmacokinetic interaction between anlotinib and amlodipine besylate in rats. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01233-w

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01233-w

Keywords: anlotinib, amlodipine, pharmacokinetics, drug-drug interaction, LC-MS/MS, rats, cytochrome P450, hypertension, cancer therapy, drug clearance, BMC Pharmacology and Toxicology, preclinical study